未来的发展，复宏汉霖将立刻专注临床药理和贸易市场未被达到的所需，激发许多安全管理性强、效用好的、病员可经济负担的改革创新海洋生物药企业产品，长期強化新产品开发、研发及商业区化的中国运营推广系统，探讨许多展览化联合概率，多方面促进展览化应用程序，造福中国许多病员团队。

Henlius Attends BIO 2022

 From June 13-16, 2022, the 2022 Biotechnology Innovation Organization International Convention (“BIO 2022”) was held in San Diego, California, USA. The conference attracted more than 3,000 exhibitors, as well as many global industry leaders and top research scholars. At the San Diego Convention Center’s booth 5107, Henlius showcased a wide range of innovative research and development accomplishments for conference attendees.

During the conference, Henlius ended with more than 90 meetings with national and international partners and multiple possible leads for in-licensing, research collaboration, or commercial right out-licensing conducted at the Henlius’ booth throughout the four-day exhibition. These discussions focused on advancing new approaches to science, including therapeutic biologics, technology platforms, immuno-oncology target combinations, and building robust partnerships to accelerate innovation. Henlius’ diversified product pipeline and international presence was attractive to attendees. Most impressive is Henlius' leading innovative product, HANSIZHUANG (serplulimab), which was the first China-based company developed anti-PD-1 mAb to be orally presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting for the first-line treatment of lung cancer. Subsequently, Henlius announced on the first day of BIO 2022 that it had entered into a license and supply agreement with Organon LLC for the exclusive global commercialization of Henlius independently developed HLX11 (Pertuzumab biosimilar) and HLX14 (Denosumab biosimilar) in ex-China countries, including mature markets such as the United States, the European Union and Japan, as well as emerging markets.

Having the goals of providing innovation and affordability for patient centric unmet medical needs, Henlius has actively expanded the global markets by leveraging its strong product development, manufacturing and quality systems, and commercialization capabilities, as well as collaborating with capable partnerships to accelerate these goals. Synergising its innovation centres in China and the US and global product development teams, the company continues to build on the momentum to expand an even more diversified innovation product pipeline and has conducted more than 20 clinical trials in China, the EU, the US, Australia, etc. with more than 70 clinical trial approvals worldwide. In terms of manufacturing, the company strictly follows the International Good Manufacturing Practice (GMP) standards for production and quality control. It has a total commercial manufacturing capacity of 48,000L currently, and all the products in the pipeline are produced in-house, accumulating vertically integrating production experience and capabilities from clinical stages to commercialized products. In terms of commercialization, Henlius has built a top tier in-house commercial team of over 800 sales force for the commercialization of the company's core oncology products such as HANQUYOU (trastuzumab biosimilar, Zercepac^® in Europe) and HANSIZHUANG. In addition, Henlius has actively collaborated with global partners such as Abbott, Accord, Cipla, Eurofarma, Organon, Jacobson Medical, KG Bio, FARMA DE COLOMBIA, and Mabxience to expand the global presence of bring innovative medicines and affordability to patients both in major and emerging markets.

Looking forward, Henlius will maintain its focus on unmet medical and market needs; develop more high-quality, affordable and innovative biologics; advance its global R&D, production, and commercialization capabilities; expand international collaborations, and accelerate building a global presence to benefit patients worldwide.